You are leaving our website

or Decline

At a glance

Our 2023 Performance Overview

182.7 £m See-through Revenue*
31.3 £m Underlying Profit Before Tax*
4.55p Underlying Basic EPS*
180.7 £m Statutory Revenue
(50.2 £m Reported Profit Before Tax

*Non-IFRS Alternative Performance Measures (‘APMs’). See-through revenue includes all sales from Nizoral as if they had been invoiced by Alliance as principal. For statutory accounting purposes the product margin relating to Nizoral sales made on an agency basis is included within Revenue, in line with IFRS 15.

Results centre

2023 Annual Report

Annual Report

Annual Report 2023 (8.7mb)


Working together to achieve more for investors

Our alliances, clear strategy and proven business model enable us to deliver consistent and sustained returns for investors.

Why Invest

Financial calendar

19Jun 2024 2023 Preliminary Results


Results centre